Every Form 4 that Alto Neuroscience Inc. (ANRO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ANRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANRO filings page.
Alto Neuroscience, Inc. director Andrew Craig Miller received a grant of stock options covering 26,000 shares of common stock at an exercise price of $20.44 per share. These options vest in 36 equal monthly installments starting on June 27, 2026, and were awarded under the company’s Non-Employee Director Compensation Policy, with no cash paid by the director for the grant.
Alto Neuroscience, Inc. President and CEO Amit Etkin reported a bona fide gift of 400,000 shares of Common Stock on May 14, 2026. The shares were transferred for estate planning purposes to the Bard on Haven Trust, an irrevocable trust for the benefit of his spouse and children, for no consideration. The trustee is independent, and Etkin has no voting, dispositive, or pecuniary interest in the trust’s holdings. After the gift, he directly holds 833,949 shares of Alto Neuroscience common stock.
Alto Neuroscience director Ramiro Sanchez received a grant of stock options for 10,958 shares of common stock. The options have an exercise price of $24.63 per share and expire on May 11, 2036. All 10,958 underlying shares will vest on the earlier of the one-year anniversary of the grant date and the company’s next annual meeting, as long as he remains in continuous service. The options were issued under Alto Neuroscience’s Non-Employee Director Compensation Policy, and Sanchez paid no cash consideration for this award. Following this grant, he holds 10,958 derivative securities directly.
Alto Neuroscience, Inc. director Christopher Nixon Cox received a grant of stock options for 10,958 shares of common stock at an exercise price of $24.63 per share. These options vest on the earlier of one year from grant or the company’s next annual meeting, provided he continues in service, and were issued under the non-employee director compensation policy without any cash payment from him. Following this grant, he holds 10,958 stock options directly.
Alto Neuroscience director Manji Husseini received a stock option grant for 10,958 shares of common stock. The option has an exercise price of $24.63 per share and expires on May 11, 2036. The shares underlying the option vest on the earlier of the one-year anniversary of the grant date and the company’s next annual meeting, as long as he remains in continuous service. According to the disclosure, the option was issued under the non-employee director compensation policy and no cash consideration was paid for the grant. Following this award, Husseini holds options covering 10,958 shares directly.
Alto Neuroscience director Andrew Dreyfus received a grant of stock options covering 10,958 shares of common stock. The options have an exercise price of $24.63 per share and expire on May 11, 2036. They vest on the earlier of the one-year anniversary of the grant date or the company’s next annual meeting, as long as he continues in service through that date. According to the disclosure, he paid no cash consideration for this award, which was issued under the company’s Non-Employee Director Compensation Policy. Following this grant, he holds options for 10,958 shares directly.
Alto Neuroscience, Inc. director York Gwill received a grant of stock options covering 10,958 shares of common stock at an exercise price of $24.63 per share. The options were issued under the company’s Non-Employee Director Compensation Policy and required no cash payment by Gwill.
The options will vest on the earlier of the one-year anniversary of the grant date and the company’s next annual meeting, as long as Gwill continues to serve through that vesting date. After this grant, he holds options for 10,958 underlying shares directly.
Alto Neuroscience, Inc. reported that President and CEO Amit Etkin had 6,227 shares of common stock withheld on March 1, 2026 to cover taxes upon vesting of previously reported restricted stock units. The shares were valued at $19.69 per share and the filing notes this was not an open market transaction. After this tax-withholding disposition, Etkin directly owned 1,233,949 common shares.
Alto Neuroscience, Inc. Chief Financial Officer & CBO Nicholas Conrad Smith reported a Form 4 transaction involving company common stock. On March 1, 2026, 2,806 shares were withheld at $19.69 per share to cover taxes upon vesting of restricted stock units, rather than through an open market trade. After this tax-withholding disposition, he directly held 24,060 common shares.
Alto Neuroscience reported that President and CEO Etkin Amit received an employee stock option grant on February 11, 2026. The option covers 306,000 shares of common stock at an exercise price of $16.71 per share and expires on February 10, 2036.
According to the vesting terms, 25% of the shares vest on February 11, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on his continued service. After this award, Amit directly holds options for 306,000 shares.
Alto Neuroscience Chief Medical Officer Adam Savitz received a grant of 124,000 employee stock options on February 11, 2026. The options have an exercise price of $16.71 per share and expire on February 10, 2036. They relate to Alto Neuroscience common stock.
According to the vesting terms, 25% of the shares underlying the option will vest on February 11, 2027. The remaining shares will then vest in equal monthly installments over the following three years, provided Savitz continues in service through each vesting date. After this grant, he directly holds 124,000 derivative securities in the form of these options.
Smith Nicholas Conrad reported acquisition or exercise transactions in a Form 4 filing for ANRO. The filing lists transactions totaling 200,000 shares. Following the reported transactions, holdings were 200,000 shares.
Alto Neuroscience reported that its Chief Operating Officer, Michael Conick Hanley Jr., received an employee stock option grant. On February 11, 2026, he was awarded options to acquire 131,000 shares of common stock at an exercise price of $16.71 per share.
The options vest over four years: 25% of the underlying shares vest on February 11, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on his continued service with the company.
Alto Neuroscience, Inc. disclosed that one of its directors received a new stock option grant. On 01/02/2026, the director was granted an option to purchase 5,243 shares of Alto Neuroscience common stock at an exercise price of $16.59 per share, expiring on 01/01/2036.
The option vests in four equal quarterly installments during 2026: 1,311 shares on March 31, 1,311 shares on June 30, 1,310 shares on September 30, and 1,311 shares on December 31, subject to the director’s continuous service. The filing notes that this option was issued under the company’s Non-Employee Director Compensation Policy in lieu of $62,000 in cash retainer fees.
Alto Neuroscience director reports new stock option grant. A board member of Alto Neuroscience, Inc. filed a Form 4 reporting receipt of a stock option covering 7,189 shares of common stock on 01/02/2026.
The option was granted under the company’s Non-Employee Director Compensation Policy in lieu of cash retainer fees of $85,000. Vesting is scheduled in four installments during 2026: 1,797 shares on March 31, 1,797 shares on June 30, 1,798 shares on September 30, and 1,797 shares on December 31, contingent on the director’s continuous service through each vesting date.
Alto Neuroscience, Inc. director compensation is disclosed through a new stock option grant. On 01/02/2026, a reporting person serving as a director received an employee stock option to buy 4,228 shares of common stock at an exercise price of $16.59 per share. The option relates to 4,228 underlying common shares and was granted under the company’s Non-Employee Director Compensation Policy in lieu of $50,000 in cash retainer fees. The option vests in four equal installments of 1,057 shares on March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026, if the director’s service continues through each vesting date.
Alto Neuroscience, Inc. reported that one of its directors received a grant of stock options. On 01/02/2026, the director was granted 3,806 stock options to purchase Alto Neuroscience common stock. These options were issued under the company’s Non-Employee Director Compensation Policy in lieu of $45,000 in retainer fees.
The options vest in four quarterly installments during 2026, subject to the director’s continued service. 952 options vest on March 31, 2026, 951 options on June 30, 2026, 952 options on September 30, 2026, and 951 options on December 31, 2026. Any unvested portion would not be earned if service ends before the relevant vesting date.